國立虎尾科技大學 |

Next Generation Kinase Inhibitors = Moving Beyond the ATP Binding/Catalytic Sites /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Next Generation Kinase Inhibitors/ edited by Paul Shapiro.
其他題名:	Moving Beyond the ATP Binding/Catalytic Sites /
其他作者:	Shapiro, Paul.
面頁冊數:	XII, 217 p. 59 illus., 56 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Cancer Research. -
電子資源:	https://doi.org/10.1007/978-3-030-48283-1
ISBN:	9783030482831

Next Generation Kinase Inhibitors = Moving Beyond the ATP Binding/Catalytic Sites /
Next Generation Kinase InhibitorsMoving Beyond the ATP Binding/Catalytic Sites /[electronic resource] :edited by Paul Shapiro. - 1st ed. 2020. - XII, 217 p. 59 illus., 56 illus. in color.online resource.

Chapter 1: Introduction to Kinases, Cellular Signaling, and Kinase Inhibitors -- Chapter 2: Overview of Current Type I/II Kinase Inhibitors -- Chapter 3: Avoiding or Co-opting ATP Inhibition: Type III, IV, V, and VI Kinase Inhibitors -- Chapter 4: Structural Features Regulating Kinase Interactions with Regulatory and Substrate Proteins -- Chapter 5: Developing Kinase Inhibitors using Computer-Aided Drug Design Approaches -- Chapter 6: A Toolbox of Structural Biology and Enzyme Kinetics Reveals the Case for ERK Docking Site Inhibition -- Chapter 7: Novel Stabilized Peptide Inhibitors of Protein Kinases -- Chapter 8: Novel peptide-based inhibitors of protein kinases -- Index.

Protein kinases are fascinating enzymes that maintain the proper function of nearly every task performed by the cells of the human body. By extracting a phosphate from the energy molecule ATP and linking it to another protein, protein kinases alter the structure and ultimate function of other proteins. In this way, protein kinases help monitor the extracellular environment and integrate signaling cues that, for the most part, are beneficial for human health and survival. However, protein kinases are often dysregulated and responsible for the initiation and progression of many types of cancers, inflammatory disorders, and other diseases. Thus, decades of research have revealed much about how protein kinases are regulated and approaches to inhibit these enzymes to treat disease. However, nearly 30 years since the identification of the first clinically beneficial small molecule protein kinase inhibitor, there are only a few examples where these drugs provide sustained and durable patient responses. The goal of this book is to provide biomedical scientists, graduate, and professional degree students insight into different approaches using small molecules to block specific protein kinase functions that promote disease. .

ISBN: 9783030482831

Standard No.: 10.1007/978-3-030-48283-1doiSubjects--Topical Terms:

668358
Cancer Research.

LC Class. No.: RC261-271

Dewey Class. No.: 614.5999

Next Generation Kinase Inhibitors = Moving Beyond the ATP Binding/Catalytic Sites /
LDR:03320nam a22003975i 4500 001 1018872
003 DE-He213
005 20200714123507.0
007 cr nn 008mamaa
008 210318s2020 gw | s |||| 0|eng d
020 $a 9783030482831 $9 978-3-030-48283-1
024 7 $a 10.1007/978-3-030-48283-1 $2 doi
035 $a 978-3-030-48283-1
050 4 $a RC261-271
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 614.5999 $2 23
245 1 0 $a Next Generation Kinase Inhibitors $h [electronic resource] : $b Moving Beyond the ATP Binding/Catalytic Sites / $c edited by Paul Shapiro.
250 $a 1st ed. 2020.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2020.
300 $a XII, 217 p. 59 illus., 56 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Chapter 1: Introduction to Kinases, Cellular Signaling, and Kinase Inhibitors -- Chapter 2: Overview of Current Type I/II Kinase Inhibitors -- Chapter 3: Avoiding or Co-opting ATP Inhibition: Type III, IV, V, and VI Kinase Inhibitors -- Chapter 4: Structural Features Regulating Kinase Interactions with Regulatory and Substrate Proteins -- Chapter 5: Developing Kinase Inhibitors using Computer-Aided Drug Design Approaches -- Chapter 6: A Toolbox of Structural Biology and Enzyme Kinetics Reveals the Case for ERK Docking Site Inhibition -- Chapter 7: Novel Stabilized Peptide Inhibitors of Protein Kinases -- Chapter 8: Novel peptide-based inhibitors of protein kinases -- Index.
520 $a Protein kinases are fascinating enzymes that maintain the proper function of nearly every task performed by the cells of the human body. By extracting a phosphate from the energy molecule ATP and linking it to another protein, protein kinases alter the structure and ultimate function of other proteins. In this way, protein kinases help monitor the extracellular environment and integrate signaling cues that, for the most part, are beneficial for human health and survival. However, protein kinases are often dysregulated and responsible for the initiation and progression of many types of cancers, inflammatory disorders, and other diseases. Thus, decades of research have revealed much about how protein kinases are regulated and approaches to inhibit these enzymes to treat disease. However, nearly 30 years since the identification of the first clinically beneficial small molecule protein kinase inhibitor, there are only a few examples where these drugs provide sustained and durable patient responses. The goal of this book is to provide biomedical scientists, graduate, and professional degree students insight into different approaches using small molecules to block specific protein kinase functions that promote disease. .
650 1 4 $a Cancer Research. $3 668358
650 0 $a Cancer research. $3 1253664
700 1 $a Shapiro, Paul. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1313970
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030482824
776 0 8 $i Printed edition: $z 9783030482848
776 0 8 $i Printed edition: $z 9783030482855
856 4 0 $u https://doi.org/10.1007/978-3-030-48283-1
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)